医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2014年
24期
147-148
,共2页
美托洛尔%COPD合并ACS
美託洛爾%COPD閤併ACS
미탁락이%COPD합병ACS
Metoprolol%COPD combined ACS
目的:探讨美托洛尔治疗慢性阻塞性肺病(COPD)合并急性冠脉综合征(aACS)的疗效观察。方法将60例COPD合并ACS患者分为观察组和对照组各30例。对照组采用常规治疗方法,不应用任何β-受体拮抗剂,观察组在常规治疗基础上使用美托洛尔治疗。评价两组治疗前后血压、心率、存活率、肺功能情况,以判断美托洛尔的治疗效果和不良反应。结果观察组患者2个月后心率、收缩压、舒张压较治疗前有显著差异(<0.05)。生存率与对照组比较有统计学差异(<0.05)。两组在对肺功能的影响上无统计学意义(P>0.05)。结论美托洛尔治疗COPD合并ACS有很好的治疗效果,而且对肺功能无影响,是临床中值得运用的可靠选择。
目的:探討美託洛爾治療慢性阻塞性肺病(COPD)閤併急性冠脈綜閤徵(aACS)的療效觀察。方法將60例COPD閤併ACS患者分為觀察組和對照組各30例。對照組採用常規治療方法,不應用任何β-受體拮抗劑,觀察組在常規治療基礎上使用美託洛爾治療。評價兩組治療前後血壓、心率、存活率、肺功能情況,以判斷美託洛爾的治療效果和不良反應。結果觀察組患者2箇月後心率、收縮壓、舒張壓較治療前有顯著差異(<0.05)。生存率與對照組比較有統計學差異(<0.05)。兩組在對肺功能的影響上無統計學意義(P>0.05)。結論美託洛爾治療COPD閤併ACS有很好的治療效果,而且對肺功能無影響,是臨床中值得運用的可靠選擇。
목적:탐토미탁락이치료만성조새성폐병(COPD)합병급성관맥종합정(aACS)적료효관찰。방법장60례COPD합병ACS환자분위관찰조화대조조각30례。대조조채용상규치료방법,불응용임하β-수체길항제,관찰조재상규치료기출상사용미탁락이치료。평개량조치료전후혈압、심솔、존활솔、폐공능정황,이판단미탁락이적치료효과화불량반응。결과관찰조환자2개월후심솔、수축압、서장압교치료전유현저차이(<0.05)。생존솔여대조조비교유통계학차이(<0.05)。량조재대폐공능적영향상무통계학의의(P>0.05)。결론미탁락이치료COPD합병ACS유흔호적치료효과,이차대폐공능무영향,시림상중치득운용적가고선택。
Objective To investigate the metoprolol treatment of chronic obstructive pulmonary disease (COPD) patients with acute coronary syndrome ef icacy (aACS)'s. Methods 60 COPD patients with ACS were divided into observation group and control group of 30 cases. Control group using conventional treatment methods, without applying anyβ-receptor antagonists, metoprolol treatment group was observed in conventional therapy. Evaluation of blood pressure, heart rate, survival rate, lung function before and after treatment of the two groups to determine the therapeutic ef ects of metoprolol and adverse reactions. Results The patients two months after the heart rate, systolic blood pressure, a significant dif erence ( <0.05) compared with pre-treatment diastolic blood pressure. There were significant dif erences ( <0.05) survival rate of the control group. 2 groups on the impact on lung function was not statistical y significant ( > 0.05). Conclusion COPD with metoprolol ACS has a good therapeutic ef ect, but had no ef ect on lung function, is worthy of clinical use and reliable choice.